Resonance Health Limited (ASX:RHT)

Market Cap	22.42M +16.2%
Revenue (ttm)	13.84M +31.4%
Net Income	769.30K
EPS	0.00
Shares Out	477.12M
PE Ratio	28.89
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	507,651
Open	0.0440
Previous Close	0.0470
Day's Range	0.0430 - 0.0470
52-Week Range	0.0330 - 0.0590
Beta	1.08
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Resonance Health

Resonance Health Limited, a healthcare technology and services company, designs, develops, manufactures, and commercializes software-as-medical devices (SaMD) in the Asia Pacific, North America, Europe, the Middle East, and Africa. It operates through SaMD, Resonance Clinical, and TrialsWest segments. The company offers FerriScan, a non-invasive MRI based solution for quantifying liver iron concentration (LIC); FerriSmart, an artificial intelligence (AI) solution for the automated real-time assessment of LIC; HepaFatScan, a non-invasive MRI-bas...

• Industry: Health Information Services
• Sector: Healthcare
• Founded: 1987
• Employees: 16
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: RHT

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 8, 2026

Data Sources Report a data error